Novo Nordisk Bets on Subscription Edge in Obesity Drugs

Novo Nordisk A/S is rolling out a subscription program offering lower monthly prices for its Wegovy weight-loss medication, available in both pill and injection forms. This move is the latest strategy to regain market share from competitor Eli Lilly & Co. in the booming obesity drug market. The Danish drugmaker aims to enhance patient access and affordability through this new pricing model. The subscription service represents a competitive maneuver to capture a larger segment of the lucrative and rapidly expanding market for obesity treatments.